Illumina, Inc. vs Kraft Heinz Co — how do they compare? Illumina, Inc. trades at $264.24 (market cap $40.43B), while Kraft Heinz Co trades at $22.44 (market cap $26.06B). The key difference: Illumina, Inc. is the larger of the two by market cap, and Kraft Heinz Co pays a 7.28% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Kraft Heinz Co for 129 Days on average.
| ILMN | KHC | |
|---|---|---|
Market Cap | $40.43B | $26.06B |
Volume | 2,948,626 | 15,326,651 |
Sector | Health | Consumer Staples |
52-Week High | $293.69 | $27.62 |
52-Week Low | $91.00 | $21.21 |
Typical Hold Time | 83 Days | 129 Days |
Enterprise Value | $41.79B | $42.38B |
Dividend Yield | — | 7.28% |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
Kraft Heinz (KHC) trades at $21.98, down 0.23% on the day, with a bearish technical signal and mixed fundamentals. Recent earnings have beaten estimates, but 2025 saw a net loss of $5.85 billion due to impairment charges, though operating cash flow remains strong at $4.46 billion. The company is executing a turnaround strategy, including a $700 million reinvestment and new product launches like Philadelphia cream cheese flavors, to revive brand relevance amid volume challenges.
The stock offers a discounted valuation with a P/E of 13.04 and P/B of 0.72, but high debt and negative ROE pose risks. Analyst consensus is cautious with a hold-heavy rating and $23.78 price target, implying modest upside. Key opportunities include cash flow stability and brand reinvestment, while risks involve persistent volume declines and competitive pressures in the consumer goods sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →